Skip to main content

Table 3 Positive telehealth satisfaction according to demographic and patient-specific factors

From: Evaluation of pediatric rheumatology telehealth satisfaction during the COVID-19 pandemic

Variable Total Score Usefulness Ease of Use Effectiveness Satisfaction/ Future Use
Age
 0–5 years 83% 65% 90% 90% 85%
 6–12 years 83% 73% 87% 87% 86%
 13–17 years 82% 76% 86% 85% 80%
 18+ years 73% 69% 75% 76% 70%
Race
 Caucasian 81% 73% 86% 84% 81%
 African American 88% 77% 90% 97% 88%
 Asian 85% 79% 86% 90% 84%
 Other 77% 62% 84% 86% 76%
Conditiona
 JIA 79% 68% 85% 84% 80%
 SLE 85% 81% 88% 88% 83%
 Inflammatory diseaseb 82% 73% 89% 84% 82%
 AMPS 79% 76% 78% 83% 78%
 Other/Unknown 83% 74% 88% 89% 82%
Time since diagnosis
 Within 6 months 84% 76% 89% 86% 84%
 Greater than 6 months 81% 72% 85% 85% 80%
Prescribed rheumatologic medication(s)
 Yes (n = 148) 82% 73% 87% 87% 82%
  Glucocorticoid therapy 82% 75% 88% 84% 81%
  No glucocorticoid therapy 83% 73% 87% 87% 83%
 No 80% 72% 84% 84% 79%
Rheumatology visit type (n = 212)
 New 80% 70% 86% 86% 79%
 Established 80% 72% 83% 84% 80%
  1. Positive satisfaction defined as responses of “agree” and “strongly agree”
  2. aJIA: juvenile idiopathic arthritis; SLE: systemic lupus erythematosus; AMPS: amplified musculoskeletal pain syndrome
  3. bDiagnoses included in the “inflammatory disease” category include Sjogren syndrome, vasculitis, juvenile dermatomyositis, chronic nonbacterial osteomyelitis, idiopathic uveitis, localized scleroderma, systemic sclerosis, Behcet syndrome, sarcoidosis, and periodic fever syndrome or auto-inflammatory disorder